From clinical trials to clinical practice: Applying CDK4/6 inhibitors in HR+/HER2– early breast cancer

touchEXPERT OPINIONS for touchONCOLOGY

Listen to three experts in breast cancer as they provide insights into the current guideline recommendations for the use of targeted therapy in patients with HR+/HER2– early breast cancer, evaluate the latest data for CDK4/6 inhibitors in this patient population and consider how to maximize the potential of these agents through risk stratification and safety considerations.

 

The experts

• Prof. Carlos Barrios: Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil
• Prof. Dr. med. Peter Fasching: University Hospital Erlangen and Comprehensive Cancer Center, Erlangen-EMN, Germany
• Dr Sonia Pernas: Catalan Institute of Oncology-Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain

 

This touchPODCAST is for healthcare professionals outside of the UK and the USA.

This activity is funded by an independent medical education grant from Novartis.

This activity is provided by touchIME.

 

For further information visit our website: 

www.touchONCOLOGY.com